Management of treatment resistance in schizophrenia

被引:267
作者
Conley, RR
Kelly, DL
机构
[1] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Catonsville, MD 21228 USA
[2] Univ Maryland, Sch Med, Dept Psychiat, Catonsville, MD 21228 USA
[3] Univ Maryland, Sch Med, Dept Pharm Practice & Sci, Catonsville, MD 21228 USA
关键词
schizophrenia; treatment resistance; antipsychotic;
D O I
10.1016/S0006-3223(01)01271-9
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
A systematic approach to the evaluation and characterization of treatment resistance in schizophrenia has become increasingly important since the introduction of the second-generation antipsychotics. The need for accurate evaluation will increase further as other new antipsychotic medications are developed. Patients with schizophrenia may manifest poor response to therapy because of intolerance to medication, poor adherence, inappropriate dosing, as hell as true resistance of their illness to antipsychotic drug therapy. Criteria for treatment-resistance are presented to help in standardizing treatment and clinical trials. As clinicians face the decision of when to change or augment antipsychotic medications, a clear understanding of the appropriate length of a treatment trial and which target symptoms respond to antipsychotic therapy is critical for maximizing response in patients with treatment-resistant schizophrenia. (C) 2001 Society of Biological Psychiatry.
引用
收藏
页码:898 / 911
页数:14
相关论文
共 171 条
  • [1] Adjunctive risperidone treatment in patients with 'clozapine-resistant schizophrenia'
    Adesanya, A
    Pantelis, C
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2000, 34 (03) : 533 - 534
  • [2] [Anonymous], 1980, DSM 3
  • [3] Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
    Arvanitis, LA
    Miller, BG
    Borison, RL
    Pitts, WM
    Sharif, ZA
    Hamner, MB
    Herz, MI
    True, JE
    Velligan, D
    Knesevich, MA
    Small, J
    Steinbook, R
    Hertzman, M
    Keck, PE
    Newcomer, JW
    Grace, J
    Rotrosen, J
    Tandon, R
    Dott, SG
    Ferguson, JM
    Addington, DEN
    MacEwan, GW
    Nair, VNP
    Shriqui, CL
    Williams, R
    Daniel, DG
    Shehi, GM
    Patterson, WM
    Merideth, CH
    [J]. BIOLOGICAL PSYCHIATRY, 1997, 42 (04) : 233 - 246
  • [4] A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia
    Azorin, JM
    Spiegel, R
    Remington, G
    Vanelle, JM
    Péré, JJ
    Giguere, M
    Bourdeix, I
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (08) : 1305 - 1313
  • [5] BACHER N, 1985, AM J PSYCHIAT, V142, P386
  • [6] EFFECT OF ADJUVANT RESERPINE TREATMENT ON CATECHOLAMINE METABOLISM IN SCHIZOPHRENIC-PATIENTS UNDER LONG-TERM NEUROLEPTIC TREATMENT
    BAGDY, G
    PERENYI
    FRECSKA, E
    SEREGI, A
    FEKETE, MIK
    TOTHFALUSI, L
    MAGYAR, K
    BELA, A
    ARATO, M
    [J]. JOURNAL OF NEURAL TRANSMISSION, 1988, 71 (01) : 73 - 78
  • [7] BAK TH, 1995, J CLIN PSYCHIAT, V56, P418
  • [8] BALDESSARINI RJ, 1988, ARCH GEN PSYCHIAT, V45, P79
  • [9] Pharmacological treatment strategies in the non-responsive schizophrenic patient
    Barnes, TRE
    McEvedy, CJB
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1996, 11 : 67 - 71
  • [10] Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial
    Beasley, CM
    Tollefson, G
    Tran, P
    Satterlee, W
    Sanger, T
    Hamilton, S
    Fabre, L
    Small, J
    Ereshefsky, L
    True, J
    Nemeroff, C
    Risch, SC
    Perry, PJ
    Potkin, SG
    Borison, RL
    James, S
    Meltzer, HY
    Iqbal, N
    Fann, WE
    Gewirtz, GR
    Landbloom, R
    RoyByrne, PP
    Tuason, VB
    Carman, JS
    Stokes, PE
    Williams, R
    Ancill, RJ
    MacEwan, GW
    Gujavarty, KS
    Jones, B
    Lohr, JB
    [J]. NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) : 111 - 123